Silverarc Capital Management
ACRS icon

Silverarc Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Silverarc Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.25M Sell
238,541
-1,707,941
-88% -$9.8M 0.15% 63
2026
Q2 		$10.3M Buy
+1,946,482
New +$8.68M 1.07% 32
2023
Q3 		– Sell
-219,229
Closed -$1.87M – 81
2023
Q2 		$2.27M Sell
219,229
-871
-0.4% -$7.88K 0.7% 42
2023
Q1 		$1.78M Sell
220,100
-132,093
-38% -$1.68M 0.74% 46
2022
Q4 		$5.55M Sell
352,193
-191,583
-35% -$3.08M 1.59% 23
2022
Q3 		$8.56M Buy
543,776
+4,231
+0.8% +$66.7K 2.9% 11
2022
Q2 		$7.53M Buy
539,545
+264,212
+96% +$3.7M 2.32% 13
2022
Q1 		$4.75M Sell
275,333
-10,893
-4% -$149K 1.96% 12
2021
Q4 		$4.16M Buy
286,226
+112,899
+65% +$1.71M 1.69% 19
2021
Q3 		$3.12M Sell
173,327
-15,392
-8% -$247K 1.76% 20
2021
Q2 		$3.31M Sell
188,719
-148,018
-44% -$3.36M 1.48% 21
2021
Q1 		$8.49M Buy
+336,737
New +$6.59M 4.63% 1

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Decheng Capital
Decheng Capital Menlo Park, California $685M AUM 129.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JHC
Jones Hill Capital New York $589M AUM
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Silverarc Capital Management's ACRS Position: Q3 2026 in Review

Silverarc Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 88% in Q3 2026, selling an estimated $9.8M and leaving 238,541 shares worth $1.25M. The position accounts for 0.15% of the portfolio, ranked #63.

Silverarc Capital Management first reported a position in ACRS in Q1 2021 and has held it in 12 quarters since. The position peaked at $10.3M in Q2 2026. 111 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Silverarc Capital Management held 238,541 shares of Aclaris Therapeutics worth $1.25M as of Q3 2026.
  • Silverarc Capital Management sold 1,707,941 Aclaris Therapeutics shares in Q3 2026, an estimated $9.8M.
  • Aclaris Therapeutics made up 0.15% of Silverarc Capital Management's portfolio in Q3 2026, its #63 holding.
  • Silverarc Capital Management first reported a position in Aclaris Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • Silverarc Capital Management's Aclaris Therapeutics position peaked at $10.3M in Q2 2026.
  • 111 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Silverarc Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.